The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine

Vaccine

Volumn 25, Issue 9, 2007, Pages 1619-1625

  Lininger, Linda A ^a   Cullum, Malford E ^a   Lyles, Mark B ^b   Bienek, Diane R ^a  

^a Naval Institute for Dental and Biomedical Research   (United States)

^b Bureau of Medicine and Surgery   (United States)

Author keywords

Anthrax; Antibody; Human; Vaccine efficacy

Indexed keywords

ANTHRAX VACCINE; ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTHRAX; ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH CENTER; HUMAN; IMMUNITY; INFORMATION PROCESSING; MAGNITUDE ESTIMATION METHOD; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNITED STATES; VACCINATION; VALIDATION PROCESS;

ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; MILITARY PERSONNEL; TIME FACTORS; VACCINATION;

EID: 33846254979     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.005     Document Type: Article

References (22)

1. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., and Ingraham N.R. Field evaluation of a human anthrax vaccine. Am J Public Health 56 (1962) 632-645
2. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 (2002) 1412-1420
3. Pittman P.R., Leitman S.F., Barrera Oro J.G., Norris S.L., Marano N.M., Ranadive M.V., et al. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diag Lab Immunol 12 6 (2005) 713-721
4. Pittman P.R., Hack D., Mangiafico J., Gibbs P., McKee K.T., Friedlander A.M., et al. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine 20 (2002) 2107-2115
5. Quinn C.P., Semenova V.A., Elie C.M., Romero-Steiner S., Greene C., Li H., et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin g antibodies to anthrax toxin protective antigen. Emer Infect Dis 8 10 (2002) 1103-1110
6. In: Joellenbeck L.M., Zwanziger L.L., Durch J.S., and Strom B.L. (Eds). The anthrax vaccine: is it safe? Does it work? (2002), National Academy Press, Washington, DC
7. Pittman P.R., Mangiafico J.A., Rossi C.A., Cannon T.L., Gibbs P.H., Parker G.W., et al. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 19 2-3 (2001) 213-216
8. Turnbull P.C.B., Broster M.G., Carman J.A., Manchee R.J., and Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52 2 (1986) 356-363
9. McBride B.W., Mogg A., Telfer J.L., Lever M.S., Miller J., Turnbull P.C.B., et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16 8 (1998) 810-817
10. Reinberg A., Schuller E., Delasnerie N., Clench J., and Helary M. Rythmes circadiens et circannuels des leucocytes, proteines totales, immunoglobulines a, g, et m, etude chez 9 adultes jeunes et sains. Nouv Presse Med 6 41 (1977) 3819-3823
11. Bouvenot G., Bartolin R., Arnaud C., deRegis M., Rakoto J.P., and Bruguerolle B. Variations circadiennes seriques des proteines totales, des igm et de la fraction c3 du complement chez quarante hommes adultes en bonne sante apparente. Pathol Biol 32 3 (1984) 173-176
12. Medical Follow-up Agency and Insitute of Medicine. An assessment of the CDC anthrax vaccine safety and efficacy research program (2003), National Academies Press, Washington, DC
13. Little S.F., and Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52 2 (1986) 509-512
14. Ivins B.E., Welkos S.L., Little S.F., Crumrine M.H., and Nelson G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun 60 2 (1992) 662-668
15. Ivins B.E., Fellows P.F., and Nelson G.O. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 12 10 (1994) 872-874
16. Ivins B., Fellows P., Pitt L., Estep J., Farchaus J., Friedlander A., et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13 18 (1995) 1779-1784
17. Fellows P.F., Linscott M.K., Ivins B.E., Pitt M.L.M., Rossi C.A., Gibbs P.H., et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19 23-24 (2001) 3241-3247
18. Ivins B.E., Pitt M.L.M., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 11-12 (1998) 1141-1148
19. Pitt M.L.M., Little S., Ivins B.E., Fellows P., Boles J., Barth J., et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 87 2 (1999) 304
20. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 32 (2001) 4768-4773
21. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L.M., Norris S.L.W., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 (2004) 422-430
22. Pittman P.R., Norris S.L., Barrera Oro J.G., Bedwell D., Cannon T.L., and McKee K.T. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 24 (2006) 3654-3660